{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:49:13Z","timestamp":1791449353886,"version":"4.3.3"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ijid.2026.109152","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:30:35Z","timestamp":1790955035000},"page":"109152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prediction of response to Buruli ulcer treatment shortening with novel beta-lactam-containing antimicrobial combinations"],"prefix":"10.1016","author":[{"given":"Umberto","family":"Villani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"D\u2019Agate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"S\u00e1ez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8480-0325","authenticated-orcid":false,"given":"Santiago","family":"Ram\u00f3n-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar Della","family":"Pasqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2026.109152_bib0001","unstructured":"The World Health Organisation. Buruli Ulcer in Africa: 20 Years of Progress. 2025."},{"issue":"5","key":"10.1016\/j.ijid.2026.109152_bib0002","first-page":"406","article-title":"Djakeaux S. Recurrence after surgical treatment of Buruli ulcer in Cote d\u2019Ivoire","volume":"96","author":"Kanga","year":"2003","journal-title":"Bull Soc Pathol Exot"},{"issue":"5","key":"10.1016\/j.ijid.2026.109152_bib0003","first-page":"471","article-title":"Relapse after surgical treatment of mycobacterium ulcerans infection (buruli ulcer): study of risk factors in 84 patients in the Democratic Republic of the Congo","volume":"69","author":"Kibadi","year":"2009","journal-title":"Med Trop Rev Corps Sante Colon"},{"issue":"8","key":"10.1016\/j.ijid.2026.109152_bib0004","article-title":"Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease)","volume":"8","author":"Yotsu","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"10.1016\/j.ijid.2026.109152_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002739","article-title":"Long term streptomycin toxicity in the treatment of Buruli ulcer: follow-up of participants in the BURULICO drug trial","volume":"8","author":"Klis","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"10232","key":"10.1016\/j.ijid.2026.109152_bib0006","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0140-6736(20)30047-7","article-title":"Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial","volume":"395","author":"Phillips","year":"2020","journal-title":"The Lancet"},{"issue":"7","key":"10.1016\/j.ijid.2026.109152_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005695","article-title":"Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase \/IS 2404 qPCR assay","volume":"11","author":"Sarpong-Duah","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"10.1016\/j.ijid.2026.109152_bib0008","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02171-18","article-title":"Oxazolidinones can replace clarithromycin in combination with rifampin in a mouse model of Buruli ulcer","volume":"63","author":"Almeida","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ijid.2026.109152_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000933","article-title":"Activities of rifampin, rifapentine and clarithromycin alone and in combination against Mycobacterium ulcerans disease in mice","volume":"5","author":"Almeida","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"10.1016\/j.ijid.2026.109152_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007126","article-title":"Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening","volume":"13","author":"Arenaz-Callao","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"10.1016\/j.ijid.2026.109152_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011867","article-title":"Amoxicillin\/clavulanate in combination with rifampicin\/clarithromycin is bactericidal against Mycobacterium ulcerans","volume":"18","author":"S\u00e1ez-L\u00f3pez","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"10.1016\/j.ijid.2026.109152_bib0012","volume":"23","author":"Johnson","year":"2022","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.ijid.2026.109152_bib0013","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bcp.16209","article-title":"Optimizing \u03b2-lactam-containing antibiotic combination therapy for the treatment of Buruli ulcer","volume":"91","author":"D\u2019Agate","year":"2025","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.ijid.2026.109152_bib0014","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2165\/11593210-000000000-00000","article-title":"Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008","volume":"50","author":"Lee","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.ijid.2026.109152_bib0015","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkz319","article-title":"How long will treatment guidelines for TB continue to overlook variability in drug exposure?","volume":"74","author":"Muliaditan","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.ijid.2026.109152_bib0016","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/clpt.2013.54","article-title":"Model-based drug development: a rational approach to efficiently accelerate drug development","volume":"93","author":"Milligan","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ijid.2026.109152_bib0018","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","article-title":"High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial","volume":"17","author":"Boeree","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.ijid.2026.109152_bib0019","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.drudis.2016.09.004","article-title":"The implications of model-informed drug discovery and development for tuberculosis","volume":"22","author":"Muliaditan","year":"2017","journal-title":"Drug Discov Today"},{"issue":"17","key":"10.1016\/j.ijid.2026.109152_bib0020","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ijid.2026.109152_bib0021","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis","volume":"371","author":"Jindani","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ijid.2026.109152_bib0022","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40475-018-0166-2","article-title":"Buruli Ulcer: a Review of the Current Knowledge","volume":"5","author":"Yotsu","year":"2018","journal-title":"Curr Trop Med Rep"},{"issue":"1","key":"10.1016\/j.ijid.2026.109152_bib0023","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.14371","article-title":"Evaluation of pharmacokinetic-pharmacodynamic relationships and selection of drug combinations for tuberculosis","volume":"87","author":"Muliaditan","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijid.2026.109152_bib0024","article-title":"Clinical and microbiological predictors of healing in Buruli ulcer disease","volume":"34","author":"Agbavor","year":"2024","journal-title":"J Clin Tuberc Mycobact Dis"},{"issue":"9","key":"10.1016\/j.ijid.2026.109152_bib0025","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1128\/AAC.00099-10","article-title":"Pharmacokinetics of Rifampin and Clarithromycin in Patients Treated for Mycobacterium ulcerans Infection","volume":"54","author":"Alffenaar","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ijid.2026.109152_bib0026","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.clpt.2004.10.002","article-title":"Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4\/5 activity and expression","volume":"77","author":"Pinto","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.ijid.2026.109152_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104390","article-title":"Therapeutic innovation in drug repurposing: Challenges and opportunities","volume":"30","author":"Recino","year":"2025","journal-title":"Drug Discov Today."}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226007873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226007873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:52:14Z","timestamp":1791445934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226007873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":26,"alternative-id":["S1201971226007873"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.109152","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of response to Buruli ulcer treatment shortening with novel beta-lactam-containing antimicrobial combinations","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.109152","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"109152"}}